In one report, a patient with an L576P KIT mutation in whom
imatinib therapy had previously failed experienced marked reduction in tumor burden in response to dasatinib treatment.
Effect of
imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia
Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R. Effect of
imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia.
Not exact matches
Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing
therapy with
imatinib.
This work, and that of colleagues Brian Druker and Novartis, led to the development of the kinase inhibitor
imatinib (Gleevec) as primary
therapy for chronic myelogenous leukemia (CML), and the discovery that
imatinib resistance is caused by BCR - ABL kinase domain mutations.